IVA
Inventiva S.A.
Set alert
3.65 USD -0.08 -2.14%
3.59 Day range 3.76
2.87 52-week range 7.15
- YTD
- -21.51%
- 1 year
- -12.05%
- Open
- 3.69
- Prev close
- 3.73
- Mkt cap
- 862.21M
- Vol
- 1.73M
- Avg vol
- 1.91M
- EPS
- -0.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.59
- High
- 3.76
- Forward P/E
- -5.34
- Beta
- 0.92
- Short ratio
- 3.38
- Inst. own
- 41.80%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Sep 25, 2026
- 50-d avg
- 4.53
- 200-d avg
- 5.07
- 1y target
- 14.62
Key statistics
- Market cap
- 1.05B
- Enterprise value
- 1.10B
- Trailing P/E
- 0.00
- Forward P/E
- -5.34
- PEG ratio
- 0.00
- Price / sales
- 155.48
- Price / book
- 0.00
- EPS (TTM)
- -2.21
- Beta
- 0.92
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 6.76M
- Revenue growth
- -89.90%
- Free cash flow
- -200.71M
- Total cash
- 99.84M
- Total debt
- 230.89M
- Return on equity
- 0.00%
- Shares outstanding
- 236.22M
- Short % of float
- 1.16%
- 50-day average
- 4.53
- 200-day average
- 5.07
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 14.62 +300.7% upside
Now 3.65
- Target (low)
- 8.80
- Target (mean)
- 14.62
- Target (high)
- 26.00
Ratings (0m) 12 12 buy · 0 hold · 0 sell
- Strong buy1
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Sep 25, 2026
Expected Sep 25, 2026. Consensus EPS estimate 0.00.
Financials — quick view
IVA Revenue — quarterly 1.92M
IVA Net income — quarterly -14.30M
IVA EPS — quarterly -0.37
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Sep 25, 2026 | Jun 30, 2026 | -0.20 | — | — | — |
| Mar 30, 2026 | Dec 31, 2025 | -0.23 | -1.07 | -0.84 | -365.22% |
| Sep 25, 2025 | Jun 30, 2025 | -0.41 | -1.89 | -1.48 | -361.73% |
| Mar 26, 2025 | Dec 31, 2024 | -0.44 | -2.19 | -1.75 | -398.10% |
| Sep 25, 2024 | Jun 30, 2024 | -0.56 | -1.01 | -0.45 | -81.10% |
| Mar 27, 2024 | Dec 31, 2023 | -0.40 | -1.25 | -0.85 | -211.66% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 17, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Mar 19, 2026 | Truist Securities | init | — | Buy |
| Jan 28, 2026 | Barclays | init | — | Overweight |
| Jan 12, 2026 | Leerink Partners | init | — | Outperform |
| Nov 18, 2025 | Guggenheim | main | Buy | Buy |
| Nov 6, 2025 | Wolfe Research | init | — | Outperform |
About Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- Website
- inventivapharma.com
News
- Truist Securities Maintains Buy on Inventiva, Raises Price Target to $18
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Progress Software, Nft And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
- Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
- Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday
- Canaccord Genuity Maintains Buy on Inventiva, Raises Price Target to $21
- Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
- Inventiva H1 2026 Earnings Call: Complete Transcript
- Earnings Scheduled For September 28, 2026
- Inventiva H1 EPS $(0.29) Misses $(0.20) Estimate, Sales $23.251K Miss $10.000M Estimate
Your note
Sign in to keep a note on IVA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Caligan Partners, LP | 3.91% | 8,163,191 | 36.33M | Jun 29, 2026 |
| Samsara BioCapital, LLC | 3.02% | 6,314,805 | 28.10M | Jun 29, 2026 |
| Paradigm Biocapital Advisors LP | 1.91% | 4,000,000 | 17.80M | Jun 29, 2026 |
| Andera Partners | 1.74% | 3,633,181 | 16.17M | Jun 29, 2026 |
| Adar1 Capital Management, LLC | 1.73% | 3,606,656 | 16.05M | Jun 29, 2026 |
| Millennium Management Llc | 1.68% | 3,512,174 | 15.63M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| abrdn World Healthcare Fund | 0.58% | 1,214,281 | 5.40M | Jun 29, 2026 |
| abrdn Life Sciences Investors | 0.52% | 1,093,492 | 4.87M | Jun 29, 2026 |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 0.46% | 969,588 | 4.31M | Apr 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 0.33% | 685,400 | 3.05M | Jul 30, 2026 |
| iShares Trust-iShares MSCI EAFE Small-Cap ETF | 0.15% | 318,275 | 1.42M | Jun 29, 2026 |
| Simplify Exchange Traded Funds-Simplify Propel Opportunities ETF | 0.15% | 313,483 | 1.39M | Jun 29, 2026 |